Related Experiment Video
Updated: Feb 12, 2026

Tear-Derived Exosomal miR-15a as New Diagnostic Tool for Diabetic Retinopathy
Published on: December 30, 2025
(Pro)renin receptor: Involvement in diabetic retinopathy and development of molecular targeted therapy
Atsuhiro Kanda1, Susumu Ishida1
1Laboratory of Ocular Cell Biology and Visual Science, Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Abstract:
The renin-angiotensin system (RAS), a crucial regulator of systemic blood pressure (circulatory RAS), plays distinct roles in pathological angiogenesis and inflammation in various organs (tissue RAS), such as diabetic microvascular complications. Using ocular clinical samples and animal disease models, we elucidated molecular mechanisms in which tissue RAS excites the expression of vascular endothelial growth factor (VEGF)-A responsible for retinal inflammation and angiogenesis, the two major pathological events in diabetic retinopathy (DR). Furthermore, we showed the involvement of (pro)renin receptor [(P)RR] in retinal RAS activation and its concurrent intracellular signal transduction (e.g., extracellular signal-regulated kinase); namely, the (P)RR-induced dual pathogenic bioactivity referred to as the receptor-associated prorenin system. Indeed, neovascular endothelial cells in the fibrovascular tissue collected from eyes with proliferative DR were immunoreactive for the receptor-associated prorenin system components including prorenin, (P)RR, phosphorylated extracellular signal-regulated kinase and VEGF-A. Protein levels of soluble (P)RR increased with its positive correlations with prorenin, renin enzymatic activity and VEGF in the vitreous of proliferative DR eyes, suggesting a close link between (P)RR and VEGF-A-driven angiogenic activity. Furthermore, we revealed an unsuspected, PAPS-independent role of (P)RR in glucose-induced oxidative stress. Recently, we developed an innovative single-strand ribonucleic acid interference molecule selectively targeting human and mouse (P)RR, and confirmed its efficacy in suppressing diabetes-induced retinal inflammation in mice. Our data using clinical samples and animal models suggested the significant implication of (P)RR in the pathogenesis of DR, and the potential usefulness of the ribonucleic acid interference molecule as a therapeutic agent to attenuate ocular inflammation and angiogenesis.
Insights
The study reveals the (pro)renin receptor [(P)RR] is key in diabetic retinopathy (DR) by driving inflammation and blood vessel growth. A novel RNA interference molecule targeting (P)RR shows promise for treating DR.
Area of Science:
- Ophthalmology
- Endocrinology
- Molecular Biology
Background:
- The renin-angiotensin system (RAS) regulates blood pressure and is implicated in diabetic microvascular complications.
- Tissue RAS contributes to pathological angiogenesis and inflammation in organs like the eye, particularly in diabetic retinopathy (DR).
- Vascular Endothelial Growth Factor (VEGF)-A is a key mediator of retinal inflammation and neovascularization in DR.
Purpose of the Study:
- To elucidate the molecular mechanisms by which tissue RAS drives retinal inflammation and angiogenesis in DR.
- To investigate the role of the (pro)renin receptor [(P)RR] in retinal RAS activation and its downstream signaling pathways.
- To assess the therapeutic potential of targeting (P)RR for DR treatment.
Main Methods:
- Analysis of ocular clinical samples from patients with proliferative DR.
- Utilized animal models of diabetic retinopathy.
- Immunohistochemistry, protein analysis, and development of a novel single-strand RNA interference (ssRNAi) molecule targeting (P)RR.
Main Results:
- Tissue RAS, particularly via (P)RR, significantly upregulates VEGF-A, promoting retinal inflammation and angiogenesis in DR.
- (P)RR activation involves intracellular signaling (e.g., ERK) and is linked to oxidative stress.
- Neovascular endothelial cells in proliferative DR eyes express components of the (P)RR-associated prorenin system.
- Increased soluble (P)RR levels correlate with prorenin, renin activity, and VEGF in vitreous from DR eyes.
- The developed ssRNAi molecule effectively suppressed diabetes-induced retinal inflammation in mice.
Conclusions:
- The (pro)renin receptor [(P)RR] plays a critical role in the pathogenesis of diabetic retinopathy (DR) by mediating inflammation and angiogenesis.
- The (P)RR-associated prorenin system and its link to VEGF-A are central to DR pathology.
- A novel ssRNAi molecule targeting (P)RR demonstrates therapeutic potential for attenuating ocular inflammation and angiogenesis in DR.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Internal Receptors
Antihypertensive Drugs: Direct Renin Inhibitors
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Gene Therapy

